Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives

• Published in: Stem cell research & therapy Vol. 13; no. 1; pp. 124 - 13
• Main Authors: Yao, Weiqi, Shi, Lei, Zhang, Yun, Dong, Haibo, Zhang, Yu
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 24.03.2022; BioMed Central; BMC
• Subjects: Acute respiratory distress syndrome; Antiviral agents; Antiviral drugs; B cells; Bacterial infections; Bacterial pneumonia; Cell therapy; Clinical trials; Coronaviruses; COVID-19; COVID-19 - therapy; Cytokine storm; Cytokines; Drugs; Edema; Epidemics; Granulocytes; Growth factors; Health aspects; Humans; Immune system; Immunomodulation; Infections; Inflammation; Influenza; Interleukin 6; Kinases; Lymphocytes; Medical research; Medicine, Experimental; Mesenchymal Stem Cells - metabolism; Mesenchyme; Morbidity; Mortality; MSC; Neutrophils; Pandemics; Patients; Permeability; Pneumonia; Proteins; Respiratory diseases; Respiratory Distress Syndrome; Review; SARS-CoV-2; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Stem cells; Stromal cells; Tumor necrosis factor-TNF; United Kingdom; Virus diseases; United Kingdom; COVID-19; MSC; Cell therapy

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread into more than 200 countries and infected approximately 203 million people globally. COVID-19 is associated with high mortality and morbidity in some patients, and thi...